We are monitoring the impact of COVID-19 on APAC Diabetic Neuropathy Market Get in touch with us for detailed analysis Know More
Pulished Date October, 2021
ID: 12212
Share on
Share on

APAC Diabetic Neuropathy Market Research Report – Segmented By Disorder, Treatment, Distribution channel, & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast | 2021 to 2026

Pulished: October, 2021
ID: 12212
Pages: 100

APAC Diabetic Neuropathy Market Size (2021 to 2026)

The size of the APAC diabetic neuropathy market is predicted to be worth USD 1.04 billion in 2021 and USD 1.77 billion by 2026, growing at a CAGR of 11.18% during the forecast period.

Diabetic neuropathy is a nervous disorder associated with diabetes mellitus. Neuropathy is seen as a common complication for both type 1 and type 2 diabetes.

The major problems in diabetic neuropathy include Diabetic Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, and Focal Neuropathy. Heart rate, blood pressure, perspiration, and digestion are all affected by diabetic automatic neuropathy. The thighs, hips, buttocks, and legs are affected by proximal diabetic neuropathy. Because of the persistent pain associated with diabetic neuropathy, daily activities might be tough.

According to a study published in the journal Diabetes Research and Clinical Practice, an estimated 477 million people will be living with diabetes by 2050. Diabetes affected around one-tenth of the world's population in 2019. Neuropathy affects between 62 percent and 72 percent of patients with diabetes. For more than 25 years, patients with neuropathy have had the highest prevalence of the condition. As a result, the treatment of diabetes has increased, with huge pharmaceutical companies investing considerably in new diabetic medications.

The link between neuropathy and diabetes has been established, and it has been determined that the majority of people with clinically confirmed diabetes are at high risk of developing neuropathy. Furthermore, according to an Asia-Pacific study published in the journal of neurology, 50 percent of people with diabetes have or will have peripheral neuropathy at some point in their lives. Diabetic neuropathy monitoring and treatment technologies and drugs to regulate and calm increased blood sugar levels are now on the market. Rising public awareness of diabetics and their long-term repercussions are expected to drive the growth of the APAC diabetic neuropathy market during the forecast period.

However, High clinical trial failure rates and stringent government requirements for product approval limit the Diabetic Neuropathy industry in the Asia Pacific.

Factors such as the increased need for better neuropathy treatments are expected to drive market expansion in the near future. In addition, many local governments and non-governmental organizations (NGOs) across the Asia Pacific are initiating efforts to raise awareness about diabetic neuropathy prevention. For example, the National Institute of Neurological Disorders and Stroke funds research into neuropathy and related issues.

The drugs used to treat neuropathic pain have had varied successes in terms of pain relief. However, the erroneous diagnosis or therapy selection, as well as side effects and the rising cost of drugs for the treatment of diabetic neuropathy, are all obstacles in the Diabetic Neuropathy Market. According to the Asian Pacific Association of Neuropathy with Diabetes, most people with clinically diagnosed diabetes diseases are at high risk of developing neuropathy.

This research report on the APAC diabetic neuropathy market has been segmented and sub-segmented into the following categories:

By Disorder:

  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy

By Treatment:

  • Drugs
    • Analgesic
      • Topical
        • Capsaicin
        • Others
      • Opioid:
        • Morphine
        • Others
      • NSAIDs
        • Ibuprofen
        • Naproxen
        • Others
    • Antidepressants:
      • TCAs
        • Amitriptyline
        • Imipramine
        • Others
      • SNRIs
        • Duloxetine
        • Others
      • SSRIs
        • Citalopram
        • Paroxetine
        • Others
    • Anticonvulsant Drugs
      • Gabapentin
      • Pregabalin
      • Topiramate
      • Others
      • Other Drugs
  • Radiotherapy
    • Transcutaneous Electrical Nerve Stimulation (TENS)
    • Others
    • Physiotherapy

By Distribution Channel:

  • Hospitals
  • Clinics
  • Retail Pharmacy
  • Online Pharmacy

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand, Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

The APAC Diabetic Neuropathy Market is expected to grow rapidly in the next years. Rising diabetes incidence and an increase in the geriatric population suffering from chronic disease are driving the diabetic neuropathy market in Asia. As a result, the Asia-Pacific region is predicted to develop at a compound annual growth rate of 7.7%. (CAGR). More than 60% of people with diabetes live in Asia, with China and India accounting for more than half of them. Hospitals equipped with X-ray machines to treat diabetic neuropathies are becoming more common as a result of an increase in healthcare awareness programs and a large number of patients. Furthermore, the growing number of diabetic patients in developing nations such as China, India, and Japan are expected to propel the APAC Diabetic Neuropathy Market forward. 

China held the largest share of the Diabetic Neuropathy market, and it is projected to account for a predominant share during the forecast period. The market growth is due to the proliferation of chronic diseases such as diabetes, the growing geriatric population, and favorable reimbursement policies. 

KEY MARKET PLAYERS:

Johnson & Johnson (Janssen Global Services, LLC), Boehringer Ingelheim GmbH, NeuroMetrix, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Lupin Limited, Pfizer Inc., Astellas Pharma Inc., Glenmark Pharmaceuticals Ltd., Arbor Pharmaceuticals, LLC and Depomed, Inc. are a few of the promising players in the APAC diabetic neuropathy market.

1. Introduction                                   

            1.1 Market Definition            

            1.2 Scope of the report                     

            1.3 Study Assumptions                      

            1.4 Base Currency, Base Year and Forecast Periods             

2. Research Methodology                             

            2.1 Analysis Design                

            2.2 Research Phases              

                        2.2.1 Secondary Research     

                        2.2.2 Primary Research          

                        2.2.3 Data Modelling 

                        2.2.4 Expert Validation          

            2.3 Study Timeline                 

3. Report Overview                            

            3.1 Executive Summary                     

            3.2 Key Inferences                 

4. Market Dynamics                           

            4.1 Impact Analysis                

                        4.1.1 Drivers  

                        4.1.2 Restraints          

                        4.1.3 Opportunities   

            4.2 Regulatory Environment              

            4.3 Technology Timeline & Recent Trends                

5. Competitor Benchmarking Analysis                                  

            5.1 Key Player Benchmarking            

                        5.1.1 Market share analysis   

                        5.1.2 Products/Service          

                        5.1.3 Regional Presence        

            5.2 Mergers & Acquisition Landscape                       

            5.3 Joint Ventures & Collaborations              

6. Market Segmentation                                

            6.1 APAC Diabetic Neuropathy Market – By Disorder:                   

                        6.1.1 Peripheral Neuropathy 

                        6.1.2 Autonomic Neuropathy

                        6.1.3   Proximal Neuropathy  

                        6.1.4 Focal Neuropathy                     

                        6.1.5 Market Size Estimations & Forecasts (2021-2026)      

                        6.1.6 Y-o-Y Growth Rate Analysis      

                        6.1.7 Market Attractiveness Index    

            6.2 APAC Diabetic Neuropathy Market – By Treatment:                

                        6.2.1   Drugs   

                        6.2.2 Radiotherapy    

                        6.2.3 Market Size Estimations & Forecasts (2021-2026)      

                        6.2.4 Y-o-Y Growth Rate Analysis      

                        6.2.5 Market Attractiveness Index    

            6.3 APAC Diabetic Neuropathy Market – By Distribution Channel:            

                        6.3.1 Hospitals

                        6.3.2    Clinics 

                        6.3.3 Retail Pharmacy

                        6.3.4 Online Pharmacy          

                        6.3.5 Market Size Estimations & Forecasts (2021-2026)      

                        6.3.6 Y-o-Y Growth Rate Analysis      

                        6.3.7 Market Attractiveness Index    

7. Geographical Landscape                            

            7.1 Asia Pacific                       

                        7.1.1 By Country        

                                    7.1.1.1 China

                                    7.1.1.2 India

                                    7.1.1.3 Japan

                                    7.1.1.4 South Korea

                                    7.1.1.5 South East Asia

                                    7.1.1.6 Australia & NZ

                                    7.1.1.7 Rest of Asia-Pacific

                        7.1.2 By Disorder:      

                        7.1.3 By Treatment:   

                        7.1.4 By Distribution Channel:           

8. Key Player Analysis                        

            8.1 Johnson & Johnson (Janssen APAC Services, LLC)                     

                        8.1.1 Business Description    

                        8.1.2 Products/Service          

                        8.1.3 Financials          

                        8.1.4 SWOT Analysis  

                        8.1.5 Recent Developments  

                        8.1.6 Analyst Overview          

            8.2 Boehringer Ingelheim GmbH                   

            8.3 NeuroMetrix, Inc.            

            8.4 Eli Lilly and Company                   

            8.5 GlaxoSmithKline plc                     

            8.6 Lupin Limited                   

            8.7 Pfizer Inc.             

            8.8 Astellas Pharma Inc.                    

            8.9 Glenmark Pharmaceuticals Ltd.              

            8.10 Arbor Pharmaceuticals              

            8.11 LLC and Depomed, Inc.              

9. Market Outlook & Investment Opportunities                               

10. Appendix                          

            List of Tables              

            List of Figures      

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and also identify the areas that are still untapped. 

  • The segment-level analysis in terms of disorder type, treatment, distribution channel, and region along with market size forecasts and estimations to detect key areas of industry growth in detail.

  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.

  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.

  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development.

  • A comprehensive list of key market players along with their product portfolio, current strategic interests, essential financial information, legal issues, SWOT analysis, and analyst overview to study and sustain the market environment.

  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies

  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions.

  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations with a strong financial foothold in the market.

  1. Asia Pacific Biostimulants Market By Disorder, From 2021 to 2026 ( USD Billion )

  2. Asia Pacific Peripheral Neuropathy Market By Region, From 2021 to 2026 ( USD Billion )

  3. Asia Pacific  Autonomic Neuropathy Market By Region, From 2021 to 2026 ( USD Billion )

  4. Asia Pacific   Proximal Neuropathy Market By Region, From 2021 to 2026 ( USD Billion )

  5. Asia Pacific Focal Neuropathy Market By Region, From 2021 to 2026 ( USD Billion )

  6. Asia Pacific Biostimulants Market By Treatment, From 2021 to 2026 ( USD Billion )

  7. Asia Pacific Biostimulants Market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  8. Asia Pacific   Hospitals Market By Region, From 2021 to 2026 ( USD Billion )

  9. Asia Pacific Clinics Market By Region, From 2021 to 2026 ( USD Billion )

  10. Asia Pacific  Retail Pharmacy Market By Region, From 2021 to 2026 ( USD Billion )

  11. Asia Pacific    Online Pharmacy Market By Region, From 2021 to 2026 ( USD Billion )

  12. Japan Biostimulants Market By Disorder, From 2021 to 2026 ( USD Billion )

  13. Japan Biostimulants Market By Treatment, From 2021 to 2026 ( USD Billion )

  14. Japan Biostimulants Market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  15. China Biostimulants Market By Disorder, From 2021 to 2026 ( USD Billion )

  16. China Biostimulants Market By Treatment, From 2021 to 2026 ( USD Billion )

  17. China Biostimulants Market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  18. India Biostimulants Market By Disorder, From 2021 to 2026 ( USD Billion )

  19. India Biostimulants Market By Treatment, From 2021 to 2026 ( USD Billion )

  20. India Biostimulants Market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  21. Australia Biostimulants Market By Disorder, From 2021 to 2026 ( USD Billion )

  22. Australia Biostimulants Market By Treatment, From 2021 to 2026 ( USD Billion )

  23. Australia Biostimulants Market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  24. South Korea Biostimulants Market By Disorder, From 2021 to 2026 ( USD Billion )

  25. South Korea Biostimulants Market By Treatment, From 2021 to 2026 ( USD Billion )

  26. South Korea Biostimulants Market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  27. Asia Pacific Diabetic Neuropathy Market By Treatment, From 2021 to 2026 ( USD Million )

  28. Asia Pacific    Drugs   Market By Region, From 2021 to 2026 ( USD Million )

  29. Japan Diabetic Neuropathy Market By Treatment, From 2021 to 2026 ( USD Million )

  30. China Diabetic Neuropathy Market By Treatment, From 2021 to 2026 ( USD Million )

  31. India Diabetic Neuropathy Market By Treatment, From 2021 to 2026 ( USD Million )

  32. Australia Diabetic Neuropathy Market By Treatment, From 2021 to 2026 ( USD Million )

  33. Asia Pacific Diabetic Neuropathy Market By Drugs, From 2021 to 2026 ( USD Million )

  34. Asia Pacific  Analgesic Market By Region, From 2021 to 2026 ( USD Million )

  35. Japan Diabetic Neuropathy Market By Drugs, From 2021 to 2026 ( USD Million )

  36. China Diabetic Neuropathy Market By Drugs, From 2021 to 2026 ( USD Million )

  37. India Diabetic Neuropathy Market By Drugs, From 2021 to 2026 ( USD Million )

  38. Australia Diabetic Neuropathy Market By Drugs, From 2021 to 2026 ( USD Million )

  39. Asia Pacific Diabetic Neuropathy Market By Analgesic, From 2021 to 2026 ( USD Million )

  40. Asia Pacific Topical Market By Region, From 2021 to 2026 ( USD Million )

  41. Japan Diabetic Neuropathy Market By Analgesic, From 2021 to 2026 ( USD Million )

  42. China Diabetic Neuropathy Market By Analgesic, From 2021 to 2026 ( USD Million )

  43. India Diabetic Neuropathy Market By Analgesic, From 2021 to 2026 ( USD Million )

  44. Australia Diabetic Neuropathy Market By Analgesic, From 2021 to 2026 ( USD Million )

  45. Asia Pacific Diabetic Neuropathy Market By Topical, From 2021 to 2026 ( USD Million )

  46. Asia Pacific Capsaicin Market By Region, From 2021 to 2026 ( USD Million )

  47. Asia Pacific Others Market By Region, From 2021 to 2026 ( USD Million )

  48. Japan Diabetic Neuropathy Market By Topical, From 2021 to 2026 ( USD Million )

  49. China Diabetic Neuropathy Market By Topical, From 2021 to 2026 ( USD Million )

  50. India Diabetic Neuropathy Market By Topical, From 2021 to 2026 ( USD Million )

  51. Australia Diabetic Neuropathy Market By Topical, From 2021 to 2026 ( USD Million )

  52. Asia Pacific Diabetic Neuropathy Market By  Opioid, From 2021 to 2026 ( USD Million )

  53. Asia Pacific Morphine Market By Region, From 2021 to 2026 ( USD Million )

  54. Asia Pacific Others Market By Region, From 2021 to 2026 ( USD Million )

  55. Japan Diabetic Neuropathy Market By  Opioid, From 2021 to 2026 ( USD Million )

  56. China Diabetic Neuropathy Market By  Opioid, From 2021 to 2026 ( USD Million )

  57. India Diabetic Neuropathy Market By  Opioid, From 2021 to 2026 ( USD Million )

  58. Australia Diabetic Neuropathy Market By  Opioid, From 2021 to 2026 ( USD Million )

  59. Asia Pacific Diabetic Neuropathy Market By NSAIDs, From 2021 to 2026 ( USD Million )

  60. Asia Pacific    Ibuprofen Market By Region, From 2021 to 2026 ( USD Million )

  61. Asia Pacific Naproxen Market By Region, From 2021 to 2026 ( USD Million )

  62. Asia Pacific Others Market By Region, From 2021 to 2026 ( USD Million )

  63. Japan Diabetic Neuropathy Market By NSAIDs, From 2021 to 2026 ( USD Million )

  64. China Diabetic Neuropathy Market By NSAIDs, From 2021 to 2026 ( USD Million )

  65. India Diabetic Neuropathy Market By NSAIDs, From 2021 to 2026 ( USD Million )

  66. Australia Diabetic Neuropathy Market By NSAIDs, From 2021 to 2026 ( USD Million )

  67. Asia Pacific Diabetic Neuropathy Market By Antidepressants, From 2021 to 2026 ( USD Million )

  68. Asia Pacific TCAs Market By Region, From 2021 to 2026 ( USD Million )

  69. Asia Pacific Naproxen Market By Region, From 2021 to 2026 ( USD Million )

  70. Asia Pacific Others Market By Region, From 2021 to 2026 ( USD Million )

  71. Japan Diabetic Neuropathy Market By Antidepressants, From 2021 to 2026 ( USD Million )

  72. China Diabetic Neuropathy Market By Antidepressants, From 2021 to 2026 ( USD Million )

  73. India Diabetic Neuropathy Market By Antidepressants, From 2021 to 2026 ( USD Million )

  74. Australia Diabetic Neuropathy Market By Antidepressants, From 2021 to 2026 ( USD Million )

  75. Asia Pacific Diabetic Neuropathy Market By TCAs, From 2021 to 2026 ( USD Million )

  76. Asia Pacific Amitriptyline Market By Region, From 2021 to 2026 ( USD Million )

  77. Asia Pacific Imipramine Market By Region, From 2021 to 2026 ( USD Million )

  78. Asia Pacific   Others Market By Region, From 2021 to 2026 ( USD Million )

  79. Japan Diabetic Neuropathy Market By TCAs, From 2021 to 2026 ( USD Million )

  80. China Diabetic Neuropathy Market By TCAs, From 2021 to 2026 ( USD Million )

  81. India Diabetic Neuropathy Market By TCAs, From 2021 to 2026 ( USD Million )

  82. Australia Diabetic Neuropathy Market By TCAs, From 2021 to 2026 ( USD Million )

  83. Asia Pacific Diabetic Neuropathy Market By  SNRIs, From 2021 to 2026 ( USD Million )

  84. Asia Pacific Duloxetine Market By Region, From 2021 to 2026 ( USD Million )

  85. Asia Pacific   Others Market By Region, From 2021 to 2026 ( USD Million )

  86. Japan Diabetic Neuropathy Market By  SNRIs, From 2021 to 2026 ( USD Million )

  87. China Diabetic Neuropathy Market By  SNRIs, From 2021 to 2026 ( USD Million )

  88. India Diabetic Neuropathy Market By  SNRIs, From 2021 to 2026 ( USD Million )

  89. Australia Diabetic Neuropathy Market By  SNRIs, From 2021 to 2026 ( USD Million )

  90. Asia Pacific Diabetic Neuropathy Market By SSRIs, From 2021 to 2026 ( USD Million )

  91. Asia Pacific  Citalopram Market By Region, From 2021 to 2026 ( USD Million )

  92. Asia Pacific   Paroxetine Market By Region, From 2021 to 2026 ( USD Million )

  93. Asia Pacific  Others Market By Region, From 2021 to 2026 ( USD Million )

  94. Japan Diabetic Neuropathy Market By SSRIs, From 2021 to 2026 ( USD Million )

  95. China Diabetic Neuropathy Market By SSRIs, From 2021 to 2026 ( USD Million )

  96. India Diabetic Neuropathy Market By SSRIs, From 2021 to 2026 ( USD Million )

  97. Australia Diabetic Neuropathy Market By SSRIs, From 2021 to 2026 ( USD Million )

  98. Asia Pacific Diabetic Neuropathy Market By Anticonvulsant Drugs, From 2021 to 2026 ( USD Million )

  99. Asia Pacific Gabapentin Market By Region, From 2021 to 2026 ( USD Million )

  100. Asia Pacific Pregabalin Market By Region, From 2021 to 2026 ( USD Million )

  101. Asia Pacific Topiramate Market By Region, From 2021 to 2026 ( USD Million )

  102. Asia Pacific Others Market By Region, From 2021 to 2026 ( USD Million )

  103. Asia Pacific Other Drugs Market By Region, From 2021 to 2026 ( USD Million )

  104. Japan Diabetic Neuropathy Market By Anticonvulsant Drugs, From 2021 to 2026 ( USD Million )

  105. China Diabetic Neuropathy Market By Anticonvulsant Drugs, From 2021 to 2026 ( USD Million )

  106. India Diabetic Neuropathy Market By Anticonvulsant Drugs, From 2021 to 2026 ( USD Million )

  107. Australia Diabetic Neuropathy Market By Anticonvulsant Drugs, From 2021 to 2026 ( USD Million )

  108. Asia Pacific Diabetic Neuropathy Market By     Radiotherapy, From 2021 to 2026 ( USD Million )

  109. Asia Pacific Transcutaneous Electrical Nerve Stimulation (TENS) Market By Region, From 2021 to 2026 ( USD Million )

  110. Asia Pacific Others Market By Region, From 2021 to 2026 ( USD Million )

  111. Asia Pacific Physiotherapy Market By Region, From 2021 to 2026 ( USD Million )

  112. Japan Diabetic Neuropathy Market By     Radiotherapy, From 2021 to 2026 ( USD Million )

  113. China Diabetic Neuropathy Market By     Radiotherapy, From 2021 to 2026 ( USD Million )

  114. India Diabetic Neuropathy Market By     Radiotherapy, From 2021 to 2026 ( USD Million )

  115. Australia Diabetic Neuropathy Market By     Radiotherapy, From 2021 to 2026 ( USD Million )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample